The risk of developing a certain subsequent malignancy subtype in MM patients with a prior malignancy diagnosis compared with those without
| . | HR . | 95% CI . | P . |
|---|---|---|---|
| Overall | 1.42 | 1.23-1.65 | <.001 |
| Hematologic (n = 193) | 1.59 | 1.04-2.42 | .032 |
| Gastrointestinal (n = 318) | 1.13 | 0.81-1.58 | .475 |
| Male reproductive (n = 204) | 0.74 | 0.44-1.26 | .276 |
| Female reproductive (n = 58) | 0.71 | 0.28-1.79 | .468 |
| Breast (n = 83) | 1.16 | 0.61-2.22 | .643 |
| Kidney and urinary tract (n = 105) | 1.40 | 0.80-2.41 | .234 |
| Melanoma (n = 58) | 2.67 | 1.43-5.00 | .002 |
| Nonmelanoma skin cancer (n = 256) | 1.99 | 1.47-2.71 | <.001 |
| Respiratory (n = 64) | 3.24 | 1.79-5.88 | <.001 |
| Oral, nasal, and pharyngeal (n = 18) | 1.30 | 0.29-5.86 | .731 |
| Endocrine (n = 24) | 0.78 | 0.18-3.37 | .736 |
| Nervous system (n = 35) | 0.86 | 0.26-2.87 | .808 |
| Bone and cartilage (n = 5) | — | — | — |
| Soft tissue and mediastinal (n = 13) | 1.91 | 0.40-9.03 | .415 |
| Unspecified tumors (n = 39) | 1.28 | 0.49-3.33 | .618 |
| . | HR . | 95% CI . | P . |
|---|---|---|---|
| Overall | 1.42 | 1.23-1.65 | <.001 |
| Hematologic (n = 193) | 1.59 | 1.04-2.42 | .032 |
| Gastrointestinal (n = 318) | 1.13 | 0.81-1.58 | .475 |
| Male reproductive (n = 204) | 0.74 | 0.44-1.26 | .276 |
| Female reproductive (n = 58) | 0.71 | 0.28-1.79 | .468 |
| Breast (n = 83) | 1.16 | 0.61-2.22 | .643 |
| Kidney and urinary tract (n = 105) | 1.40 | 0.80-2.41 | .234 |
| Melanoma (n = 58) | 2.67 | 1.43-5.00 | .002 |
| Nonmelanoma skin cancer (n = 256) | 1.99 | 1.47-2.71 | <.001 |
| Respiratory (n = 64) | 3.24 | 1.79-5.88 | <.001 |
| Oral, nasal, and pharyngeal (n = 18) | 1.30 | 0.29-5.86 | .731 |
| Endocrine (n = 24) | 0.78 | 0.18-3.37 | .736 |
| Nervous system (n = 35) | 0.86 | 0.26-2.87 | .808 |
| Bone and cartilage (n = 5) | — | — | — |
| Soft tissue and mediastinal (n = 13) | 1.91 | 0.40-9.03 | .415 |
| Unspecified tumors (n = 39) | 1.28 | 0.49-3.33 | .618 |
Two-sided P < .05 was considered statistically significant, shown in boldface.